Detail akcie BIOMED-LUBLIN online

Business Summary: Synthaverse SA formerly known as Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Poland-based company operating in the Life Science industry, dealing primarily with the production of medicines. The Company focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The Company offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The Company supplies its products to 50 countries around the world.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Synthaverse SA revenues decreased 4% to PLN29.1M. Net income decreased 69% to PLN1M. Revenues reflect Traditional Segment decrease of 19% to PLN14.2M, Other Countries segment decrease of 22% to PLN10.7M, European Union (Region) segment decrease of 2% to PLN4.2M. Net income also reflects BCG Segment income decrease of 38% to PLN2.3M, Traditional Segment income decrease of 58% to PLN725K.